Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Common Equity (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Common Equity readings, the most recent being $3.3 billion for Q4 2025.

  • On a quarterly basis, Common Equity rose 25.62% to $3.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 billion, a 25.62% increase, with the full-year FY2025 number at $3.3 billion, up 25.62% from a year prior.
  • Common Equity hit $3.3 billion in Q4 2025 for Neurocrine Biosciences, up from $3.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $3.3 billion in Q4 2025 to a low of $1.2 billion in Q1 2021.
  • Median Common Equity over the past 5 years was $1.9 billion (2023), compared with a mean of $2.0 billion.
  • Biggest five-year swings in Common Equity: surged 72.15% in 2021 and later rose 6.27% in 2025.
  • Neurocrine Biosciences' Common Equity stood at $1.4 billion in 2021, then rose by 24.29% to $1.7 billion in 2022, then soared by 30.69% to $2.2 billion in 2023, then grew by 16.03% to $2.6 billion in 2024, then rose by 25.62% to $3.3 billion in 2025.
  • The last three reported values for Common Equity were $3.3 billion (Q4 2025), $3.0 billion (Q3 2025), and $2.7 billion (Q2 2025) per Business Quant data.